|
Christmas, Brian J; Rafie, Christine I; Hopkins, Alexander C et al. (2018) Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs. Cancer Immunol Res 6:1561-1577
|
|
Saung, May Tun; Muth, Stephen; Ding, Ding et al. (2018) Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. J Immunother Cancer 6:118
|
|
Deshwar, Amar B; Sugar, Elizabeth; Torto, Deirdre et al. (2018) Diagnostic intervals and pancreatic ductal adenocarcinoma (PDAC) resectability: a single-center retrospective analysis. Ann Pancreat Cancer 1:
|
|
Johnson 3rd, Burles A; Yarchoan, Mark; Lee, Valerie et al. (2017) Strategies for Increasing Pancreatic Tumor Immunogenicity. Clin Cancer Res 23:1656-1669
|
|
Diehl, Adam; Yarchoan, Mark; Hopkins, Alex et al. (2017) Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors. Oncotarget 8:114268-114280
|
|
Shroff, Rachna T; Yarchoan, Mark; O'Connor, Ashley et al. (2017) The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. Br J Cancer 116:1402-1407
|
|
Yarchoan, Mark; Xing, Dongmei; Luan, Lan et al. (2017) Characterization of the Immune Microenvironment in Hepatocellular Carcinoma. Clin Cancer Res 23:7333-7339
|
|
Croessmann, Sarah; Wong, Hong Yuen; Zabransky, Daniel J et al. (2017) PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity. Breast Cancer Res Treat 162:451-464
|
|
Saung, May Tun; Zheng, Lei (2017) Current Standards of Chemotherapy for Pancreatic Cancer. Clin Ther 39:2125-2134
|
|
Yarchoan, Mark; Johnson 3rd, Burles A; Lutz, Eric R et al. (2017) Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer 17:209-222
|
Showing the most recent 10 out of 178 publications
